TICKERNERD
Menu
RXSTRXSTHealthcare · Medical Devices

RXST Stock Forecast: RxSight, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$6.02
+1.01% on the day

The 10 Wall Street analysts covering RxSight, Inc. hold a median 12-month price target of $6.75 — +12.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$250.4M
Ticker Nerd rank
51 / 100
Median analyst target
$6.75
Analysts covering
10
Revenue$33.7M+0.3% y/y
Operating income−$13.8M
Net income−$12.1M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.0%
1M
−14.5%
YTD
−42.2%
1Y
−36.1%
From 52W high
−54.0%
From 52W low
+31.2%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RXST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores RxSight, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Quality
71
Size
65
Issuance
59
Accruals
53
Volatility
39
Value
39
Momentum
31
Growth
26

Revisions (72): Analysts have, on balance, been raising their forecasts.

Growth (26): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RXST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RXST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26RXSTHigh $11.00Median $6.75Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
1 Buy7 Hold2 Sell
Low $6.00Median $6.75High $11.00

The green dot is the last close — the median target sits +12.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Aug 2026StifelMaintainsHold$8.00 → $7.00
6 Aug 2026UBSMaintainsNeutral$5.50 → $6.30
28 July 2026UBSAssumesNeutral$9.00 → $5.50
7 July 2026B of A SecuritiesMaintainsUnderperform—
7 July 2026B of A SecuritiesMaintainsUnderperform$8.00 → $6.50
7 July 2026NeedhamReiteratesBuy$11
7 July 2026NeedhamReiteratesBuy—
7 May 2026NeedhamMaintainsBuy—
7 May 2026Wells FargoMaintainsEqual-Weight—
9 Mar 2026StifelMaintainsHold—
26 Feb 2026NeedhamReiteratesBuy—
26 Feb 2026Piper SandlerMaintainsNeutral—
26 Feb 2026UBSMaintainsNeutral—
20 Jan 2026Piper SandlerMaintainsNeutral—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
6 Nov 2025JP MorganMaintainsUnderweight—
6 Nov 2025NeedhamMaintainsBuy—
6 Nov 2025Wells FargoMaintainsEqual-Weight—
8 Aug 2025NeedhamMaintainsBuy—
8 Aug 2025StifelMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RXST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RXST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, RxSight, Inc. returned −36.1% against +17.5% for the S&P 500, dividends included.

RXST vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Oct 25Jan 26Apr 26Jul 26RXSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RXST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

RxSight, Inc. (RXST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.3×

Cheaper than 91% of US stocks

Price / sales
2.0×

Cheaper than 53% of US stocks

Price / book
1.0×

Cheaper than 74% of US stocks

EV / EBITDA
−1.0×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
0.3%

Higher than 28% of US stocks

Earnings growth (YoY)
0.3%

Higher than 36% of US stocks

Gross margin
76.7%

Higher than 88% of US stocks

Operating margin
−40.8%

Higher than 18% of US stocks

Net margin
−36.8%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−17.3%

Higher than 32% of US stocks

Return on assets
−10.4%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

RxSight, Inc. (RXST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • RxSight, Inc. has a market value of $250.4M and an enterprise value of $52.2M.

  • Revenue in the twelve months to 30 June 2026: $127.6M. The latest quarter grew 0.3% year on year.

  • Net income over the same four quarters: −$46.9M, a −36.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.13.

  • Free cash flow in the twelve months to 30 June 2026: −$27.2M.

  • Shares outstanding: 41.6M.

  • Trailing P/E: −6.3×; forward P/E: −8.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • RxSight, Inc. employs 461 people — $277K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

RXST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
RXSTRxSight, Inc.$250.4M
51
INFUInfuSystem Holdings, Inc.$242.0M
100
STIMNeuronetics, Inc.$230.9M
64
LABStandard BioTools, Inc.$269.1M
35
ELMDElectromed, Inc.$227.3M
94
TLSITriSalus Life Sciences, Inc.$279.0M
34
TMCITreace Medical Concepts, Inc.$287.4M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own RxSight, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RXST news & analysis

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

GlobeNewsWire · 26 Aug 2026neutral

RxSight, Inc. announced it will participate in the Wells Fargo Healthcare Conference on September 9, 2026 in Boston. A live and archived webcast will be available on the company's investor relations website.

Why it matters — The company's participation gives RXST watchers an opportunity to hear management's presentation, which may offer insight into the company's outlook during an investor event.

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

RxSight, Inc. (RXST) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item presents the company's earnings call discussion material.

Why it matters — A RxSight watcher would review the transcript for management commentary on its Q2 2026 results and outlook.

RxSight Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

RxSight reported second-quarter revenue of $33.7 million, including $6.5 million from its strategic collaboration with Alcon. Management withdrew full-year 2026 financial guidance as new CEO Aziz Mottiwala conducts a broader assessment of the business.

Why it matters — A RxSight watcher would care because the withdrawal of full-year guidance and the new CEO's business review signal potential strategic changes and reduced forward visibility for the company.

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

RxSight reported a Q2 loss of $0.11 per share, narrower than the Zacks Consensus Estimate of a $0.21 loss but wider than the $0.08 loss posted in the year-ago quarter. The company also beat revenue estimates for the period.

Why it matters — A narrower-than-expected quarterly loss and a revenue beat indicate RxSight's results came in ahead of what analysts had anticipated.

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

GlobeNewsWire · 5 Aug 2026neutral

RxSight, Inc. reported its financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. The announcement was made on August 5, 2026, via GlobeNewswire.

Why it matters — RXST watchers would care because the company disclosed its latest quarterly financial performance and revised guidance on its full-year 2026 outlook.

FAQ

Frequently asked questions about RXST stock

What is the RXST stock price forecast for 2026-2027?

The 10 Wall Street analysts covering RxSight, Inc. have a median 12-month price target of $6.75, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RXST stock a buy right now?

Of the 10 analysts covering RxSight, Inc., 1 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks RxSight, Inc. 51 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RXST?

As at 12 Sept 2026, RxSight, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will RXST stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +12.1% from the last close, and Ticker Nerd's factor model ranks RxSight, Inc. 51 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RXST stock forecast for 2030?

No analyst covering RxSight, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.

How has RXST stock performed over the past year?

RxSight, Inc. returned -36.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does RxSight, Inc. do?

RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery.

What is the latest news on RXST?

The most recent item we track (GlobeNewsWire, 26 Aug 2026): "RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference". RxSight, Inc. announced it will participate in the Wells Fargo Healthcare Conference on September 9, 2026 in Boston. A live and archived webcast will be available on the company's investor relations website.

Company

About RxSight, Inc.

RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals. This platform allows doctors to customize and optimize a patient’s visual acuity after implantation, addressing a major need in premium cataract care. RxSight serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, with its products used in the U.S. cataract surgery market and selected international markets through distribution partners. Headquartered in Aliso Viejo, California, RxSight operates as a specialized medical device business centered on adjustable intraocular lens technology and post-surgical vision refinement.

CEO Mr. Aziz Mottiwala M.B.A. · 461 employees · United States · https://rxsight.com